FDA Puts Cord Blood Product Policy Into Practice
This article was originally published in The Pink Sheet Daily
Executive Summary
The New York Blood Center submitted the HemaCord BLA in response to the agency’s move to pull umbilical cord blood transplantation into the regulatory fold; the agency announced in 2009 that a BLA or IND would be required for the products after Oct. 20, 2011.